Literature DB >> 1684130

(+)-6,7-benzomorphan sigma ligands stimulate dopamine synthesis in rat corpus striatum tissue.

R G Booth1, R J Baldessarini.   

Abstract

The benzomorphan sigma ligands, (+)-N-allylnormetazocine (NANM) and (+)-pentazocine, but not (+)-cyclazocine, stereospecifically stimulated dopamine synthesis in minces of rat corpus striatum by 15-23% over basal values at 0.1-1.0 microM. The effect of (+)-NANM and (+)-pentazocine was blocked by the reported sigma antagonist, BMY-14802 but not by the opiate antagonist naloxone. These results suggest that these (+)-benzomorphans may act as agonists at putative sigma heteroreceptors on striatal nerve terminals, or through an indirect mechanism, to modulate dopamine synthesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684130     DOI: 10.1016/0006-8993(91)90159-s

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  The effect of the pyridyl nitrogen position in pyridylpiperazine sigma ligands.

Authors:  Lidiya Stavitskaya; Michael J Seminerio; Marilyn M Matthews-Tsourounis; Rae R Matsumoto; Andrew Coop
Journal:  Bioorg Med Chem Lett       Date:  2010-03-01       Impact factor: 2.823

Review 2.  The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

Authors:  Danielle O Sambo; Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Pharmacol Ther       Date:  2018-01-31       Impact factor: 12.310

3.  Targeting sigma receptors: novel medication development for drug abuse and addiction.

Authors:  Rae R Matsumoto
Journal:  Expert Rev Clin Pharmacol       Date:  2009-07       Impact factor: 5.045

4.  Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine.

Authors:  Michael J Seminerio; Matthew J Robson; Ahmed H Abdelazeem; Christophe Mesangeau; Seshulatha Jamalapuram; Bonnie A Avery; Christopher R McCurdy; Rae R Matsumoto
Journal:  AAPS J       Date:  2011-12-20       Impact factor: 4.009

5.  CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice.

Authors:  Nidhi Kaushal; Michael J Seminerio; Jamaluddin Shaikh; Mark A Medina; Christophe Mesangeau; Lisa L Wilson; Christopher R McCurdy; Rae R Matsumoto
Journal:  Neuropharmacology       Date:  2011-07-07       Impact factor: 5.250

6.  AC927, a σ receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells.

Authors:  Nidhi Kaushal; Meenal Elliott; Matthew J Robson; Anand Krishnan V Iyer; Yon Rojanasakul; Andrew Coop; Rae R Matsumoto
Journal:  Mol Pharmacol       Date:  2011-11-18       Impact factor: 4.436

7.  Sigma (σ) receptor ligand, AC927 (N-phenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice.

Authors:  Michael J Seminerio; Nidhi Kaushal; Jamaluddin Shaikh; Jason D Huber; Andrew Coop; Rae R Matsumoto
Journal:  Pharmacol Biochem Behav       Date:  2010-12-02       Impact factor: 3.533

8.  Attenuation of methamphetamine-induced effects through the antagonism of sigma (sigma) receptors: Evidence from in vivo and in vitro studies.

Authors:  Rae R Matsumoto; Jamaluddin Shaikh; Lisa L Wilson; Shreedeepalakshmi Vedam; Andrew Coop
Journal:  Eur Neuropsychopharmacol       Date:  2008-08-27       Impact factor: 4.600

9.  Acute effects of sigma ligands on the extracellular DOPAC level in rat frontal cortex and striatum.

Authors:  K Matsuno; K H Matsunaga; S Mita
Journal:  Neurochem Res       Date:  1995-02       Impact factor: 3.996

10.  The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking.

Authors:  Valentina Sabino; Pietro Cottone; Yu Zhao; Malliga R Iyer; Luca Steardo; Luca Steardo; Kenner C Rice; Bruno Conti; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.